Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurotoxicity: later-stage trial registry
1 of 11 indexed Neurotoxicity trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Neurotoxicity: 11 US clinical trials tracked, 1 recruiting.
Neurotoxicity is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 3 of these trials.
Enrollment posture brief
Registry condition neurotoxicity
OPEN 1 | RECR 9% | LATE 6 | EARLY 1 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Cancers (9% recruiting · 11 trials)
Neurotoxicity lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurotoxicity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurotoxicity is recruiting below its size-band peers.
1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neurotoxicity research.
Alliance for Clinical Trials in Oncology accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Neurotoxicity enrolment sits around 104 participants.
Median target enrolment is 104 among the 11 trials that report a genuine target (sentinel values excluded). 4 of those (36.4%) plan for fewer than 100 participants.
-
Neurotoxicity research is mostly interventional.
8 interventional and 3 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
M.D. Anderson Cancer Center
NCT06144151
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Eastern Cooperative Oncology Group
NCT00978458
A Study to Compare the Long-term Outcomes After Two Different Anaesthetics
Murdoch Childrens Research Institute
NCT03089905
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
NCT00369564
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology
NCT00489411
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00046891
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Alliance for Clinical Trials in Oncology
NCT00316914
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
Radiation Therapy Oncology Group
NCT01417507
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
University of California, San Francisco
NCT00755313
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
University of California, San Francisco
NCT00003072
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
Virginia Commonwealth University
NCT01196442
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurotoxicity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurotoxicity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurotoxicity page
11 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Neurotoxicity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alliance for Clinical Trials in Oncology sponsors the most Neurotoxicity trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurotoxicity condition card totals 11 registered trials; most-linked intervention placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.